Can you take semaglutide and liraglutide together?

Why does combining two GLP-1 medicines cause problems rather than better results?

Semaglutide and liraglutide belong to the same class of medicines: GLP-1 receptor agonists. That means both attach to exactly the same receptor sites in the gut, pancreas and brain to reduce appetite, slow how quickly food leaves the stomach and affect blood-sugar regulation. Using two medicines with identical targets does not compound the benefit in the way that, say, a GLP-1 medicine might be paired with a different class acting on a completely separate pathway. What it does compound is the load on those receptors and the stress placed on your digestive system.

The practical consequence is a substantially elevated risk of the gastrointestinal side effects that already appear at the top of both medicines' known profiles: nausea, vomiting, diarrhoea, and abdominal pain. In isolation these are typically mild-to-moderate and settle as the body adjusts. Stack two GLP-1 agents and that tolerability window shrinks considerably. There is also the question of the MHRA Drug Safety Updates for this class, which include a January 2026 alert on acute pancreatitis as an infrequent but serious risk, a risk that would not diminish by running two GLP-1 medicines at once.

No clinical trial has studied concurrent use of semaglutide and liraglutide as a weight-management strategy, because the combination has no sound pharmacological rationale. Prescribers assessing you through a regulated service would decline this combination on that basis alone. If you want a fuller picture of how these two medicines compare individually, our page on liraglutide and semaglutide covers their differences in detail.

Are semaglutide and liraglutide even the same kind of medicine?

They are the same class but meaningfully different molecules. Liraglutide is an older GLP-1 agonist; it was the active ingredient in Saxenda, which was licensed for weight management in the UK, and in Victoza for type 2 diabetes. Semaglutide is a newer, structurally distinct GLP-1 agonist with a longer half-life, which is why it can be taken once weekly rather than daily. The differences matter clinically: trial data for semaglutide 2.4mg (Wegovy) showed around 15% average weight loss over 68 weeks in the STEP 1 trial, compared with roughly 5–8% historically seen with liraglutide at its licensed dose, and if you are exploring the dose options within the semaglutide range, our page on semaglutide 7mg explains where that strength sits in the broader treatment journey. For a side-by-side look at how the two medicines differ, the page asking whether liraglutide and semaglutide are the same addresses that directly.

Saxenda (liraglutide for weight management) is no longer widely available in the UK following supply discontinuation by Novo Nordisk in 2023. Victoza (liraglutide for diabetes) remains available. Neither is dispensed by nume. This is worth knowing if you have come across liraglutide being discussed in older articles or forums, the landscape has moved, and semaglutide-based options have largely replaced it in clinical practice.

A question our prescribers hear fairly regularly is whether taking two related medicines might speed things up. It is understandable, progress can feel slow, particularly around times when motivation dips, like a holiday return or the first week back to routine in January. But speed of action is not a reason to combine medicines that share a mechanism. The right lever is clinical: adjusting the dose of a single, licensed treatment with a prescriber's oversight.

What weight-loss medicines are actually licensed in the UK right now?

For weight management specifically, the currently licensed injectable options available through private prescription in the UK are Wegovy (semaglutide, by Novo Nordisk) and Mounjaro (tirzepatide, by Eli Lilly). They are not interchangeable or combinable. Mounjaro is a dual GIP and GLP-1 receptor agonist (it activates a second gut-hormone receptor that semaglutide does not) which is a genuinely different mechanism, not simply a higher dose of the same thing. You can read more about semaglutide as a treatment and the Wegovy injection specifically on our information pages.

As of June 2026, there is also an oral semaglutide option: the Wegovy tablet, approved by the MHRA on 11 June 2026 as the first oral GLP-1 medicine licensed for weight management in the UK. It follows a different dosing schedule from the injection (1.5mg escalating to 25mg) and has a specific morning-fasting requirement. It is a third option, not something to layer on top of the injection. Our weight-loss treatment overview sets out all three options clearly.

Ozempic is also semaglutide but is licensed for type 2 diabetes, not weight loss, combining it with Wegovy or treating it as an equivalent is a common misconception. The page on taking Ozempic and semaglutide together explains why that combination is equally unsuitable.

What should you do if you want to switch between GLP-1 medicines or add a second treatment?

If your current treatment is not delivering the results you hoped for, the answer is a clinical review, not addition of a second GLP-1 agent. A prescriber will look at whether the current dose has been optimised, whether a switch to a different mechanism (tirzepatide rather than semaglutide, for example) would be appropriate, or whether lifestyle factors alongside treatment need adjustment. That assessment has to be personal and documented, not based on a general query.

All of that is exactly what a regulated online prescribing service handles. At nume, a GPhC-registered Independent Prescriber personally reviews every consultation the same day, if you are considering a switch or wondering whether your current treatment is the right fit, a free consultation is the practical next step. Our clinical team's approach is described on the clinical team page, and if you have questions before starting, the FAQs page covers the most common ones. When you are ready, check your eligibility to speak with a prescriber.